The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
TheraCryf PLC formally known as Eve is a clinical stage therapeutics company that is developing a new generation of innovative therapeutics in oncology and behavioral brain disorders.
Their strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma1.
The company was formerly known as Evgen Pharma plc, and it acquired Chronos Therapeutics in April 20241.
TheraCryf’s clinical asset is SFX-01, a patented sulforaphane-based medicine1. They are also working on neuropsychiatry assets that use novel chemistry to address highly relevant targets in brain health1.
TheraCryf is focusing on developing commercially successful products, targeting certain cancers and behavioural brain disorders1. They have several ongoing projects, including:
SFX-01 and glioblastoma: Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times1.
NCE Ox-1 in Addiction and Anxiety Disorders: TheraCryf has a candidate stage antagonist molecule targeting the orexin 1 receptor with high specificity1.
NCE Atypical DAT inhibitor in Fatigue and Narcolepsy: The Company has a candidate stage atypical inhibitor of the brain dopamine transporter mechanism1.
Upon reviewing the Regulatory News Service announcement concerning the holdings, it appears that major shareholders maintain a strong sense of confidence.
Considering the ambitions surrounding Bio Markers and the burgeoning interest from prominent Bio Companies, it is prudent to deliberate whether it's too soon to deem the product a valuable asset or if the company is merely a minor player in an arena of giants.
Despite these uncertainties, the current share price presents an opportunity that, in my view, justifies an investment of a significant sum.
The Risk to me is a placing , anything can happen .....be prudent and sensible
I added today on H&L if that helps?
Or is everyone hanging on to their sits saying I'm not selling ? x
Tree shake incoming.....probably x
Favorable news or disastrous news..time to make your bets :) 😀
Unfortunately with some of Oppenheimer statements especially inhis last statement does have some bearing.
If a supplier is involved in negative activities, such as accusations of insider trading, the supermarket will conduct thorough due diligence to determine if the supplier poses a liability to their brand, and if so, they will terminate the relationship. However, seeking revenge in this manner seems poorly planned.
@trade wizard89 I do understand. This is about the 2 idiots that were lying to all us shareholders about gummies and how they were selling but telling the truth.
Callum came in , rescued the company ( without him chill would of been gone) got the family to invest quite a bit and started turning the company round.
You really can't make this up., callum either impeccable conduct gets suspended on suspicion and the 2 dummies before ( Who f#$king lied , committed deception) moved aside without sanction.
The idiots who suspended him , won't be able to fill callum shoes !!!
this is poppy****. i'm no longer invested here but callum is a decent, hardworking gentleman.
this is just so rivals can get the edge of chill.
callum, you probably reading this post. you are a decent, hardworking gentleman, forget this nonsense, you brought chill back from the brink
Regarding the termination of the vice president's employment due to gross misconduct, it's noted that he was attempting to establish a company in Greenland. This action suggests some prior knowledge. It's worth mentioning that he did not appeal the dismissal decision. Additionally, amidst concerns about financial losses, diversifying one's investment portfolio might be a prudent approach, given the volatility of the stock market.
Have they found substantial gas deposits?
Exposure to new clients is always beneficial, offering endless opportunities. However, it's crucial not to overlook the significant risk of rejection with transplants.
Therefore, any strategies to mitigate this risk are highly desirable; will be used.
It's leaped on price on h& l from 2.41 to 2.51
I think this has all to play for ....long term that is.........Goodluck all those who are holding........including me :) 😀
The share price has been rising cautiously, although most of the time it's been on the leader board.
Goodluck all
Let's see , the momentum is building on speculation alone.
Big buys after working hours , interesting?
Agreed :)
@mr magorium,
Yes, I ve been extremely fortunate to be here.
I agree about your double digits thoughts, any ideas on actual share price it could potentially rise too?
If it announces its raise its 35 million and is now applying tor its license, this will move